Atai Beckley N.V (ATAI) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−3.7x

Market Cap

$2.74B

MomentumView details →

1D Return

+0.68%

YTD Return

+79.22%

RSI (14)

63.9

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−3.7x

Market Cap

$2.74B

RSI (14)

63.9

MomentumView details →

1D Return

+0.68%

YTD Return

+79.22%

SummaryUpdated Jun 1, 2026

Atai Life Sciences N.V. (NASDAQ:ATAI) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Berlin, Germany. The company went public in June 2021 and focuses on developing innovative therapeutic candidates for various mental health disorders. Atai operates through a platform approach, advancing multiple drug candidates simultaneously across different stages of clinical development, with a particular emphasis on novel treatments for conditions like treatment-resistant depression, anxiety disorders, and substance use disorders.

Ask drillr about Atai Beckley N.V →

ProfitabilityView details →

Gross Margin

86.25%

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−378.87%

ROA (TTM)

−252.35%

Asset Turnover

0.02x

GrowthView details →

Revenue YoY

+93.72%

EPS YoY

—

FCF YoY

−64.38%

Revenue CAGR 3Y

+159.87%

EPS CAGR 3Y

—

EBITDA YoY

—

EarningsView details →

EPS (Actual)

−$0.09

EPS Surprise

15.64%

Beats (12Q)

7/12

Next Q EPS Est

−$0.12

Avg Surprise (4Q)

−8.02%

Rev Surprise

121.07%

Capital & dividendView details →

Debt/Equity

0.02x

Current Ratio

8.58x

Quick Ratio

8.58x

Div Yield

—

Div Rate

—

Div Growth 1Y

+1438.46%

Financials snapshotView financials →

Revenue (TTM)

4.47M

Net Income (TTM)

−668.19M

Op. CF (TTM)

−127.78M

Next earningsNov 12, 2026 →

Latest newsMore news →

Kahn Swick & Foti, LLC announced an investigation into the adequacy of price and process in the proposed sale of AtaiBeckley Inc.18d ago

Atai Beckley Inc's stock reached a 52-week high of $7.22, reflecting a 110% gain over the last six months and a 71.89% increase over the past year.30d ago

Similar companies

国发股份600538.SH 健之佳605266.SH Shanghai Pioneer Holding Ltd01345.HK 第一医药600833.SH ST葫芦娃605199.SH 诚意药业603811.SH Find similar companies →

Latest newsMore news →

Kahn Swick & Foti, LLC announced an investigation into the adequacy of price and process in the proposed sale of AtaiBeckley Inc.18d ago Atai Beckley Inc's stock reached a 52-week high of $7.22, reflecting a 110% gain over the last six months and a 71.89% increase over the past year.30d ago